A method was developed, using commercially available immunoaffinity chromatography cleanup cartridges, followed by detection by gas chromatography/mass spectrometry, to screen for residues of the hormone growth promotants diethylstilbestrol, dienestrol, hexestrol, and zeranol in bovine urine. The single-laboratory, in-house validation included assessment of recoveries, repeatability, linearity of response, detection capability, and specificity (cross-reactivity) with a suite of antibiotics and other hormonal growth promotants. The method was validated for screening at a target concentration of 2.0 mg/L in urine. The detection capabilities for the analytes were diethylstilbestrol, 0.24; dienestrol, 0.15; hexestrol, 0.84; and zeranol, 0.28 mg/L.
H ormonal growth promotants (HGPs) are substances with anabolic properties that are sometimes administered to livestock to increase feed efficiency and formation of lean muscle mass, and accelerate attainment of market weight. Those HGPs with estrogenic or androgenic activity are also used as veterinary drugs to treat malignant neoplasms and to control lactation and the reproductive cycle (1) . Among the HGPs used for these purposes are diethylstilbestrol (DES), dienestrol (DIEN), hexestrol (HEX), and zeranol (ZER). DES, DIEN, and HEX are structurally similar synthetic nonsteroidal estrogens, often collectively referred to as stilbenes. ZER, a derivative of benzoxacyclotetradecin, is synthesized from zearalenone, a mycotoxin produced by Fusarium graminearium. It is also a nonsteroidal estrogen. Side effects of the use of these substances include edema, alterations of liver functions, gastrointestinal disturbances, and (in males) thromboembolic risks (1) . The structures of these compounds are presented in Figure 1 .
Although the use of DES and other stilbenes is not permitted in food animals in North America, the use of all HGPs in food animals is banned in the European Union (EU), and no residues of these substances are allowed in meat products sold there. To meet EU requirements, cattle producers in a number of exporting countries have developed "hormone-free cattle" programs, where animals are certified to have been grown to market weight without the use of HGPs. National authorities are required to collect and test bovine urine for the presence of these HGPs in order to demonstrate that cattle raised for export to the EU are free of these substances (2, 3) . For cattle to be acceptable to the EU, the HGPs must not be detectable in urine by a method capable of detecting residues at a concentration of 2.0 mg/L or higher (4) . This level defines the minimum required performance limit (MRPL) for the analytical method. To meet the EU regulations, the Canadian Food Inspection Agency (CFIA) required a suitable screening method for these HGPs in bovine urine.
An existing CFIA method for DES, DIEN, HEX, and ZER in tissue, based on a method by Covey et al. (5) , was extended to bovine urine. The original gas chromatography/mass spectrometry (GC/MS) determination of the analytes was retained, and a new sample preparation methodology, based on commercially available immunoaffinity chromatography (IAC) columns, was incorporated into the method. This approach was adopted to minimize the amount of time and resources needed to develop and validate the method, and reduce familiarization time for the technical staff. The new screening method was validated for the reliability of detection of the analytes at a concentration of 2.0 mg/L in fortified blank urine samples. The single-laboratory, in-house validation included assessment of recoveries, repeatability, linearity of response, detection capability (CCb), and selectivity. -Transfer 100 mL mixed working standard solution to a 15 mL glass centrifuge tube just before evaporation of column eluates, as described below.
METHOD

Apparatus
Sample Preparation
All urine samples are kept below 0°C until assayed. Two test portions of each sample are prepared separately for ZER and for stilbenes analyses using 2 different immunoaffinity columns.
Thaw 60 mL blank urine and 12 mL each sample overnight at 4°C. Transfer 2´6 mL test portions of each thawed sample urine and 10´6 mL portions thawed blank urine into separate 15 mL polypropylene centrifuge tubes. Centrifuge each at 4000´g for 10 min. Decant 5.0 mL portions of supernatant from each tube into separate fresh tubes. Prepare 2 sets of fortified urine matrix standards and QC samples by fortifying portions of blank urine as described above. One set will be used for the ZER analysis, the other for stilbenes analysis.
Extraction and Cleanup
Load the ZER immunoaffinity columns into the vacuum manifold and let column storage buffer run through columns. Equilibrate each column with 15 mL diluted column wash buffer. Load first set of samples, QC sample, and matrix standards onto separate columns and let urine elute just to top of bed under gravity flow only. Wash each column with 2 portions of 5 mL diluted wash buffer, followed by 5 mL water. Elute each column with 4 mL 70% ethanol under gravity flow only. Wash columns with additional 10 mL 70% ethanol in water before loading more samples. These columns can be used a total of 10 times before being discarded. Stilbenes are extracted from the second set of samples, QC sample, and matrix standards using the same procedure as described for ZER, with the following change: stilbenes are eluted from stilbene immunoaffinity columns with 3 mL 70% ethanol under gravity flow only.
Prepare GC/MS chemical standard in centrifuge tube as described above. Evaporate contents of all tubes just to dryness at 60°C under gentle stream of nitrogen. Add 50 mL mixed working internal standard solution and 1 mL ethyl acetate to each centrifuge tube. Evaporate contents of all centrifuge tubes just to dryness. To each 100 mL autosampler vial add 2 mL DCB working solution. Add 25 mL ethyl acetate to each centrifuge tube, mix on a Vortex mixer 10 s, transfer contents to autosampler vials, and cap.
GC/MS Determination
GC/MS operating parameters are given in Tables 1 and 2 . This method is applied both to detect ZER using zearalane as internal standard, and stilbenes using DES-d 8 as internal standard. The ion source of the MS is tuned using the Maximum Sensitivity Autotune function of the Chemstation software with perfluorotributylamine (PFTBA) as the mass calibrant. The source is cleaned whenever the ratio of the abundances of ion m/z 502 versus ion m/z 69 falls below 1.0%. The autosampler, for each sample and standard, draws up 2.0 mL derivatizing agent, 0.2 mL air, and 3.0 mL sample. Derivatization of analytes takes place in the heated injection port.
Calculations and Calibration
The GC/MS chemical standard is run to determine retention times for the analytes. Typical retention times are given in Table 2 Calibration curves are generated for each analyte by plotting SumRatios against concentration using results of the analyses of fortified matrix standards. The results of the analysis of the QC sample are used to construct a control chart for each analyte to monitor the day-to-day intralaboratory performance of the procedure. DCB is used to monitor day-to-day performance of the GC/MS. 
Method Validation
Validation of the method was performed in 3 phases. The validation effort was divided into phases so that we could review the data generated in each phase and identify and correct problems before proceeding further.
The purpose of phase 1 was to confirm the linearity of the instrumental response to chemical standards over the concentration range of interest. Phase 1 consisted of chemical standard response curves generated from urine equivalent concentrations of 0, 1, 2, 3, 4, and 5 mg/L for each analyte, each concentration in duplicate, each curve generated on separate days.
The purpose of phase 2 was to assess the quality of the urine matrix-based calibration curves and accuracy and precision of determinations at the target concentration. Phase 2 consisted of 4 runs, each comprised a set of matrix standards fortified by the analyst at urine equivalent concentrations of 0.0, 1.0, 2.0, and 4.0 mg/L to generate calibration curves, plus 6 additional blank urine test portions fortified at 2.0 mg/L urine equivalent.
The purpose of phase 3 was to assess the accuracy and precision of the determination of analytes present in fortified urine blanks over the concentration range of interest. Phase 3 consisted of 2 batches of 6 spikes prepared by fortifying test portions of blank urine at multiple concentrations. Samples were provided as randomized blind samples to the analyst after preparation by a third party. Fortification concentrations were in the range of 1.0 to 4.0 mg/L urine equivalent. Six pairs of blind spikes were prepared for stilbenes, and 9 pairs of blind spikes were prepared for ZER. Calibration curves were generated as in phase 2.
The screening threshold concentration, above which a sample is declared suspect, was determined for each analyte according to the principles given in the drafts of the EU Commission Decision Document SANCO/1085/2000 (6) available when this work was done, which has been finalized and issued as EU Commission Decision 2002/657/EC (7), as follows. For each analyte, the determined concentrations of all phase 2 fortified samples, phase 2 matrix standards at 2.0 mg/L, and phase 3 blind spikes at 2.0 mg/L were sorted from lowest to highest values. The lowest value meeting or exceeding the 5th percentile was chosen as the screening threshold concentration.
The CCb values for each analyte were determined according to the principles given in SANCO/1085/2000 (6) . Decision limits (CCa) were calculated as intermediate values in the calculation of CCb, but are not reported here. As defined in 2002/657/EC (7), CCa is " ...the limit at and above which it can be concluded with an error probability of a that a sample is noncompliant." CCb is the lowest analyte concentration "...at which a method is able to detect truly contaminated samples with a statistical certainty of 1-b" (7) . For banned substances, a is set at 0.01 (1% error rate) and b is set at 0.05 (5% error rate). The CCb is required to be at or lower than the MRPL. In this study, the calibration curve procedure was applied using the matrix-based standards which were used to generate the 6 calibration curves from validation phases 2 and 3. The y-intercepts and the standard errors of the y-intercept (SE int ) were calculated from a linear regression analysis of the pooled calibration data. For each analyte, CCa was calculated as the corresponding concentration at the y-intercept plus 2.33´SE int . CCb was calculated as the corresponding concentration at CCa plus 1.64´SE int . Although the strict interpretation of SANCO/1085/2000 (6) requires that, for banned substances, CCa be determined using standards with concentrations at or above the MRPL in equidistant steps, and that CCb be determined using standards with concentrations at and below the MRPL in equidistant steps, the use of standards bracketing the MRPL was considered a practical compromise to reduce the number of analyses required for validation of the method.
The potential for interferences caused by the presence of other commonly encountered veterinary drug residues was assessed by conducting a selectivity study. Two test portions of blank urine were fortified with a mix of the following antibiotic compounds and HGPs to give a final concentration of 25 mg/L urine equivalent each: penicillin G, tilmicosin, tylosin, sulfathiazole, sulfamethazine, sulfadimethoxine, oxytetracyline, tetracycline, chlortetracycline, 17a-estradiol, testosterone, stanolone, boldenone, androstenedione, melengestrol acetate, methyltestosterone, pregnanediol, ethisterone, norgesterel, progesterone, and stanozolol. Two more test portions were fortified with the same mix to 25 mg/L urine equivalent each, and with ZER, DES, DIEN and HEX to 2.0 mg/L urine equivalent concentration each. A fifth test portion of blank urine was left unfortified. These 5 test portions were processed through the IAC columns and the concentrations of analytes determined by GC/MS.
Results and Discussion
Phase 1 Validation
The data used to generate the response curves were averages of single determinations of duplicate standards at each concentration. Linearity was assessed using the method of Cassidy and Janosky (8) , in which the y-intercept-corrected slope at each data point, calculated as (response -y-intercept)/concentration, is plotted against concentration. Response curves are considered linear if the individual slopes deviate less than a predetermined value, typically 10%, from the average slope of the response curve and are randomly distributed above and below the average slope. The response curves were considered linear according to the criteria above, and the linear regression R values of the response curves (data not shown) were all >0.997. 
Phase 2 Validation
Figures 2 and 3 present typical SIM mass chromatograms from GC/MS analyses of blank urine fortified with the analytes at 2 mg/L. Table 3 summarizes the results of the calibration regression analyses from phase 2. The data used to generate calibration curves were single determinations of 1 matrix standard at each concentration. For 11 of 12 curves, the correlation coefficients were >0.99. For all runs, the response curves were considered linear according to the criteria described above. Table 4 summarizes the results of determinations of the analytes in the fortified blank urine test portions. The average measured concentrations were within 12% of the fortification level. The coefficients of variation (CV) ranged from 1.0 to 12.4%. Matrix-based calibration curves were used for all subsequent analyses.
Phase 3 Validation
The results of the determinations of blind-spiked samples are summarized in Table 5 . Average recoveries for individual analytes were ZER, 88.9%; DES, 103.2%; DIEN, 100.0%; HEX, 100.8%.
Selectivity Study
No significant responses were noted at expected retention times of analytes in the blank or in the 2 test portions fortified with the mix of antibiotic substances and HGPs. The response of the analytes was not affected by the presence of added substances.
Overall Method Performance
The ability of the method to maintain relative ion intensities over the term of the validation study is illustrated by the data presented in Table 6 . The relative ion intensities were generated from analyses of the phase 2 and 3 matrix-based calibration standards and fortified blanks. In all but one case, the CV values of the relative ion intensities were within the permitted tolerances for relative ion intensities as recommended in the EU Commission Decision document 2002/657/EC (7). The ion peak ratio 414/207 (not shown) for HEX-(TMS) 2 was zero in all cases.
Because the method is primarily intended to be used for screening for residues present at a concentration of 2.0 mg/L or greater, the overall performance of this method in determining target analytes in blank urine fortified at this concentration 
cis-DES-(TMS)
2 Detection capability, determined from combined data used to generate the 6 calibration curves from validation phases 2 and 3.
trans-DES-(TMS)
was assessed. The summary presented in Table 7 is derived from all phase 2 matrix standards at 2.0 mg/L, phase 2 fortified samples, and phase 3 blank spikes at 2.0 mg/L. Based on the screening threshold concentrations calculated for each analyte, a working screening threshold concentration of 1.5 mg/L was adopted for all analytes. The calculated CCb values are all less than one-half the target concentration of 2.0 mg/L.
Conclusions
A screening procedure using IAC cleanup followed by GC/MS was developed and validated for the detection of DES, DIEN, HEX, and ZER in bovine urine at a target level of 2.0 mg/L. Average recoveries of each of the 4 analytes from blank urine fortified at the target level ranged from 96 to 106%, with CV values of 4.1-14.0%. The CCb values ranged from 0.15 to 0.84 mg/L, less than one-half the target level. There were no interferences from a suite of antibiotic compounds and HGPs added to samples at a concentration of 25 mg/L.
